CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ISR Immune System Regulation Holding AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ISR Immune System Regulation Holding AB (publ)
Retzius vag 11
Phone: +46 705 42 79 39p:+46 705 42 79 39 SOLNA, 171 65  Sweden
This company is no longer actively traded on any major stock exchange.
Business Summary
ISR Immune System Regulation Holding AB (publ) is a Sweden-based research company within the area of immunotherapy. The Company is focused the development of drug therapies for viral infections, in particular human immunodeficiency virus (HIV). The Company's product candidate, ISR048, is undergoing phase II of clinical trials for HIV indications. It provides a resistance profile, which does not require co-dosing with a boosting agent. A second generation anti-HIV drug candidate, ISR049, is in preclinical development. The Company's another drug candidate in development, ISR050, shows immunostimulatory properties that are being explored in vitro and in animal models of chronic infections, such as tuberculosis.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2021Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board AndersMilton 72
Chief Executive Officer OlaWinqvist 1/1/2018
Chief Financial Officer GunnarModalen 61
Director HansGlise
Director GunnarJardelov 75

Business Names
Business Name
ISR HBV Technology AB
ISR Immune System Regulation AB
ISR Immune System Regulation Holding AB
ISR Oncology AB

General Information
Outstanding Shares: 69,008,951 (As of 12/31/2022)
Stock Exchange: STO
Email Address: info@israb.se


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024